-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Milestone Pharmaceuticals is a biopharmaceutical company focusing on the development and commercialization of innovative cardiovascular drugs
.
The company today announced that it has reached an exclusive license and cooperation agreement with Jixing Pharmaceutical ("Jixing") to develop in Greater China for patients with paroxysmal supraventricular tachycardia (PSVT) and other cardiovascular diseases The experimental drug Etripamil, and its commercialization will be realized after approval
.
"Our vision is to benefit patients with PSVT around the world from Etripamil, and this cooperation marks an important step towards the realization of this vision.
At the same time, through this cooperation we have also consolidated our financial position and improved our Executive ability
.
" said Joseph Oliveto, President and CEO of Milestone Pharmaceuticals
.
"Etripamil has the potential to change the treatment model of PSVT
.
According to the terms of the agreement, Milestone will grant Jixing the exclusive license to develop and commercialize Etripamil for PSVT patients in Greater China
.